A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.

Minna Lehtisalo,Suvi Taskinen,E Katriina Tarkiainen,Mikko Neuvonen,Jenni Viinamäki,Maria Paile-Hyvärinen,Tuomas O Lilius,Tuija Tapaninen,Janne T Backman,Aleksi Tornio,Mikko Niemi

British journal of clinical pharmacology（2023）

引用 10|浏览10

暂无评分

摘要

These data suggest roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics. Poor SLCO1B1 or ABCG2 function genotypes may increase the risk of rosuvastatin-induced myotoxicity. Reduced doses of rosuvastatin are advisable for patients with these genotypes.

查看译文

关键词

ABCG2,SLCO1B1,SLCO2B1,pharmacogenomics,rosuvastatin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要